NASDAQ:CTMX - CytomX Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.05 +0.28 (+2.03 %)
(As of 11/15/2018 11:43 AM ET)
Previous Close$13.77
Today's Range$13.56 - $14.14
52-Week Range$12.75 - $35.00
Volume4,684 shs
Average Volume402,332 shs
Market Capitalization$622 million
P/E Ratio-12.19
Dividend YieldN/A
Beta1.46
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
Previous Symbol
CUSIPN/A
Phone650-515-3185

Debt

Debt-to-Equity RatioN/A
Current Ratio5.48
Quick Ratio5.48

Price-To-Earnings

Trailing P/E Ratio-12.19
Forward P/E Ratio-7.85
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.62 million
Price / Sales8.83
Cash FlowN/A
Price / CashN/A
Book Value$3.50 per share
Price / Book4.01

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-68.90%
Return on Equity-65.03%
Return on Assets-12.67%

Miscellaneous

Employees93
Outstanding Shares45,010,000
Market Cap$622 million
OptionableOptionable

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.11. The biotechnology company earned $12.51 million during the quarter, compared to analyst estimates of $16.42 million. CytomX Therapeutics had a negative net margin of 68.90% and a negative return on equity of 65.03%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

9 analysts have issued 1-year price objectives for CytomX Therapeutics' shares. Their forecasts range from $21.00 to $40.00. On average, they expect CytomX Therapeutics' stock price to reach $35.8571 in the next year. This suggests a possible upside of 156.1% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.

What is the consensus analysts' recommendation for CytomX Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (11/9/2018)
  • 2. Cann analysts commented, "Loss per share was $0.53, compared to our estimated EPS of $0.00. This was primarily the result of higher than expected operating expenses, which exceeded our estimate by 26.7%. R&D expense of $27.5 million was higher than our estimated $19.1 million. In addition, collaboration revenue was lower than expected due to a change in collaboration revenue recognition. A detailed, and promising, pipeline and regulatory update was provided and is included in this report." (11/6/2018)
  • 3. HC Wainwright analysts commented, "We have valued CytomX Therapeutics based on a discounted cash flow (DCF) assessment that is driven by a combination of CX-072 future sales and BMS-986249 future royalties on net sales." (9/13/2018)

Has CytomX Therapeutics been receiving favorable news coverage?

Media coverage about CTMX stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytomX Therapeutics earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
  • Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)
  • Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
  • Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
  • Ms. Danielle Olander, Sr. VP of Talent & Admin. Operations

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (8.60%), Perceptive Advisors LLC (5.91%), Renaissance Technologies LLC (3.38%), Point72 Asset Management L.P. (2.95%) and Victory Capital Management Inc. (1.98%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Russell Investments Group Ltd., First Trust Advisors LP, Panagora Asset Management Inc., GSA Capital Partners LLP, Virtus ETF Advisers LLC, Vident Investment Advisory LLC and AMP Capital Investors Ltd. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Victory Capital Management Inc., Perceptive Advisors LLC, BlackRock Inc., Candriam Luxembourg S.C.A., Sphera Funds Management LTD. and Renaissance Technologies LLC. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $14.00.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $622 million and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is http://www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Featured Article: What is a stock buyback?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel